Showing results (2291-2300 of 3,105) with videos related to

Sort By:
Pageof 311
Drug Safety|November 1, 2023
Drug Utilisation Patterns of Alternatives to Ranitidine-Containing Medicines in Patients Treated with Ranitidine: A Network Analysis of Data from Six European National DatabasesJohnmary T Arinze, Maria A J de Ridder, Dina Vojinovic, et al.
Drug Safety|October 7, 2023
Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network StudyOskar Gauffin, Judith S Brand, Sara Hedfors Vidlin, et al.
Drug Safety|July 25, 2023
Managing Cardiovascular and Cancer Risk Associated with JAK InhibitorsVictor Yang, Tue W Kragstrup, Christopher McMaster, et al.
Drug Safety|July 7, 2023
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance AssessmentYamin Shu, Lei Wang, Yiling Ding, et al.
Drug Safety|August 2, 2023
Use of Bisphosphonates and the Risk of Skin Ulcer: A National Cohort Study Using Data from the French Health Care Claims DatabaseClément Jambon-Barbara, Claire Bernardeau, Julien Bezin, et al.
Drug Safety|August 9, 2023
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New ZealandMuireann Walton, Vadim Pletzer, Thomas Teunissen, et al.
Drug Safety|August 8, 2023
Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary PanelJoanne Wing Yan Chiu, Soo Chin Lee, James Chung-Man Ho, et al.
Drug Safety|June 2, 2023
Sustained Decline of Direct General Practitioner Reporting of Adverse Drug Reactions in Australia and Paucity in Details of Australian Reports in Safety AdvisoriesIan W Boyd, John McEwen
Drug Safety|June 13, 2023
Nephrotoxicity of Amoxicillin and Third-Generation Cephalosporins: An Updated ReviewAnne-Sophie Garnier, Guillaume Drablier, Marie Briet, et al.
Drug Safety|June 10, 2023
Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated DataFahed Al-Azzawi, Israa Mahmoud, François Haguinet, et al.
Pageof 311